Atebrioz (zilurgisertib)

Name: Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: Perspective and time frame
Published: 2026-09-27T12:28:00-04:00

Fibrodysplasia ossificans progressiva

Also known as INCB000928

Manufacturer: Mirum Pharmaceuticals
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in October 2026
Last updated: October 1, 2026

Section

Economic information and modeling report Budget impact model

Perspective and time frame

1 evidence topic · 1 source

Palovarotene budget impact analysis submitted to CADTH: perspective and time horizon

“The BIA was undertaken from the perspective of a Canadian public payer over a 3-year time horizon (Q3 of 2023 through Q2 of 2026) using an epidemiologic approach.” (opens the source at this quote in a new tab)